Safety Profiles of Neurokinin-Targeted Therapies for VMS

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP

Key Takeaways

Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
Notable adverse events were observed, and the safety profile was compared with fezolinetant and traditional treatments, indicating its potential as an alternative.

Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

Now Viewing

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP: 9.Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP: 10.Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Video content above is prompted by the following:

(PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
(FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?